ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

Figure 5 ADAMTS13 is associated with progression-free survival and overall survival in patients with hepatocellular carcinoma receiving sorafenib treatment. Hepatocellular carcinoma (HCC) patients with an ADAMTS13:AC ≥ 78.0 had significantly longer progression-free survival (A) and overall survival (B) than those with an ADAMTS13:AC < 78.0. Solid and dotted lines indicate HCC patients with an ADAMTS13:AC ≥ 78.0 and an ADAMTS13:AC < 78.0, respectively. ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity.